【个人简介】

李迎君，教授，第三层次“南山学者”优秀人才，广州医科大学呼吸疾病国家重点实验室PI，博士生导师。2006年本科毕业于吉林大学；2015年在中国科学院大学（广州生物医药与健康研究院）获得博士学位，导师为丁克教授；2015至2019分别在马里兰大学巴尔的摩分校和约翰霍普金斯大学（师从著名华人化学生物学家刘钧教授）从事博士后研究。2019至2023年任南方科技大学研究副教授兼生物医药研究院院长助理。以第一作者或通讯作者在Science Translational Medicine (Science 子刊), Signal Transduction and Targeted Therapy, Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry等专业学术期刊发表19篇论文。主持包括国家自然科学基金原创探索项目在内的7项科研项目，作为核心成员参与国家重点研发计划、广东省重点领域研发计划等项目。申请专利三十多项，包括国际专利（WIPO）7项。作为核心发明人，共同研发了一项处于Ⅲ期临床的1.1类新药及一项临床前候选药物。担任Pharmaceutical Fronts杂志青年编委，J. Med. Chem., Eur. J. Med. Chem.等多个专业杂志审稿人。

【研究方向】

1）药物化学，靶向抑制剂设计合成研究；

2)抗病毒/免疫药物研发；

3）活性小分子靶标/药理机制鉴定相关的药物化学生物学研究。

【科研项目】

1. 国家自然基金委青年科学基金项目，82204194，2023/01-2025/12，30万元，在研，主持。

2. 国家自然基金委原创探索计划项目，82150206，2022/01-2023/12，80万元，主持。

3. 科技部国家重点研发计划项目，2021YFC0865100， 2021/10- 2022/09，核心成员参与。

【代表性论文及著作】

1. Zhou, Q. F.^#; Yang, S. D.^#; Cao, L.^#; Yang, Y^#; Xu, T. F.^#; Chen, Q. S.; Lu, H. Z.; Li, Y. J.*; Guo, D. Y.*; Zhang, X. M.*, Preclinical characterization and anti-SARS-CoV-2 efficacy of ATV014: an oral cyclohexanecarboxylate prodrug of 1 '-CN-4-aza-7,9-dideazaadenosine C-nucleoside. Signal Transduction and Targeted Therapy 2023, 8 (1).

2. Cao, L. ^#; Li, Y. ^#*; Yang, S. ^#; Li, G. ^#; Zhou, Q. ^#; Sun, J. ^#; Xu, T.; Yang, Y.; Liao, R.; Shi, Y.; Yang, Y.; Zhu, T.; Huang, S.; Ji, Y.; Cong, F.; Luo, Y.; Zhu, Y.; Luan, H.; Zhang, H.; Chen, J.; Liu, X.; Luo, R.; Liu, L.; Wang, P.; Yu, Y.; Xing, F.; Ke, B.; Zheng, H.; Deng, X.; Zhang, W.; Lin, C.; Shi, M.; Li, C.-M.; Zhang, Y.; Zhang, L.; Dai, J.; Lu, H.; Zhao, J. *; Zhang, X. *; Guo, D. *, The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants. Science translational medicine 2022, eabm7621-eabm7621.

3. Yongzhi Chen^#, Qifan Zhou^#, Fan Pan, Binhao Rong, Renwei Xiao, Yuanmei Wen, Jingyuan Song, Zhengchao Tu, Shuwen Liu*, Yingjun Li*, Xumu Zhang*. Synthesis and Anti-Influenza Virus Activity of Substituted Dibenzoxepine-Based Baloxavir Derivatives. Eur. J. Med. Chem., 2024,doi: 10.1016/j.ejmech.2024.116922.

4. Chen Qishu; Zhou Qifan; Li Guanguan ; Li Shuo; li yingjun; Zhang Xumu; Optimized kilogram-scale synthesis and impurity identification of SHEN26 (ATV014) for treating COVID-19, Organic Process Research & Development. 2024, 28, 6, 2188–2195.

5. Qishu Chen, Qifan Zhou, Sidi Yang, Fan Pan, Hongqi Tao, Yuanmei Wen, Yang Chao, Cailing Xie, Weixin Ou, Deying Guo*, Yingjun Li*, Xumu Zhang*. Identification of S-Adenosyl homocysteine (SAH) Analogue as SARS-CoV-2 nsp14 N7Methyltransferase Inhibitors. Bioorganic Chemistry. 2024

6. Zhou, Q. F. ^#; Luo, Y. Z. ^#; Zhu, Y. J. ^#; Chen, Q. S.; Qiu, J. F.; Cong, F. *; Li, Y. J. *; Zhang, X. M. *, Nonsteroidal anti-inflammatory drugs (NSAIDs) and nucleotide analog GS-441524 conjugates with potent in vivo efficacy against coronaviruses. European Journal of Medicinal Chemistry 2023, 249.

7. Yang, Y. ^#; Cao, L. ^#; Yan, M. ^#; Zhou, J.; Yang, S.; Xu, T.; Huang, S.; Li, K.; Zhou, Q.; Li, G.; Zhu, Y.; Cong, F.; Zhang, H. *; Guo, D. *; Li, Y. *; Zhang, X. *, Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2. Antiviral research 2023, 213, 105586.

8. Cheng, H. M. ^#; Fu, L. B. ^#*; Yang, X. ^#; Yang, Y. J.; Zhang, Z. N.; Tao, Y.; Wan, J. T.; Tu, Z. C.; Chen, J. X. *; Li, Y. J. *, Screening and identification of 3-aryl-quinolin-2-one derivatives as antiviral agents against influenza A. Journal of Medical Virology 2023, 95 (1).

9. Yang, Y. J. ^#; Yu, Q. C. ^#; Hu, L. ^#; Dai, B. T.; Qi, R. X.; Chang, Y.; Zhang, Q. W. *; Zhang, Z. *; Li, Y. J. *; Zhang, X. M. *, Enantioselective semisynthesis of novel cephalotaxine esters with potent antineoplastic activities against leukemia. European Journal of Medicinal Chemistry 2022, 244.

10. Li, Y. J. ^#*; Huang, Y. J. ^#; Cheng, H. M. ^#; Xu, F.; Qi, R. X.; Dai, B. T.; Yang, Y. J.; Tu, Z. C.; Peng, L. J. *; Zhang, Z. *, Discovery of BRAF/HDAC Dual Inhibitors Suppressing Proliferation of Human Colorectal Cancer Cells. Frontiers in Chemistry 2022, 10.

11. Li, Y. ^#; Cao, L. ^#; Li, G.; Cong, F.; Li, Y.; Sun, J.; Luo, Y.; Chen, G.; Li, G.; Wang, P.; Xing, F.; Ji, Y.; Zhao, J.; Zhang, Y.; Guo, D. *; Zhang, X. *, Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. Journal of Medicinal Chemistry 2022, 65 (4), 2785-2793.

12. Li, Y. ^#; Pasunooti, K. K.; Peng, H.; Li, R.-J.; Shi, W. Q.; Liu, W.; Cheng, Z.; Head, S. A.; Liu, J. O. *, Design and Synthesis of Tetrazole- and Pyridine-Containing Itraconazole Analogs as Potent Angiogenesis Inhibitors. ACS Medicinal Chemistry Letters 2020, 11 (6), 1111-1117.

13. Yang, W. ^#; Li, Y. ^#; Ai, Y.; Obianom, O. N.; Guo, D.; Yang, H.; Sakamuru, S.; Xia, M.; Shu, Y. *; Xue, F. *, Pyrazole-4-Carboxamide (YW2065): A Therapeutic Candidate for Colorectal Cancer via Dual Activities of Wnt/beta-Catenin Signaling Inhibition and AMP-Activated Protein Kinase (AMPK) Activation. Journal of Medicinal Chemistry 2019, 62 (24), 11151-11164.

14. Li, Y. ^#; Pasunooti, K. K. ^#; Li, R.-J.; Liu, W.; Head, S. A.; Shi, W. Q.; Liu, J. O. *, Novel Tetrazole-Containing Analogues of Itraconazole as Potent Antiangiogenic Agents with Reduced Cytochrome P450 3A4 Inhibition. Journal of Medicinal Chemistry 2018, 61 (24), 11158-11168.

【所获荣誉和奖励】